Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab
GEMCAD - 2103//MO4
Phase 2 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab for Squamous cell carcinoma of the anal canal is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Squamous cell carcinoma of the anal canal
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active